NASDAQ:MRNA - Moderna Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $228.00
  • Forecasted Upside: 52.05 %
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
▲ +7.1 (4.97%)

This chart shows the closing price for MRNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Moderna Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRNA

Analyst Price Target is $228.00
▲ +52.05% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $228.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 52.05% upside from the last price of $149.95.

This chart shows the closing price for MRNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 13 investment analysts is to hold stock in Moderna. This rating has held steady since July 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 9 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 9 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 8 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 9 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2022SVB LeerinkLower Price TargetUnderperform$80.00 ➝ $70.00Low
5/17/2022Piper SandlerLower Price TargetOverweight$348.00 ➝ $214.00Medium
4/12/2022Morgan StanleyBoost Price TargetEqual Weight$205.00 ➝ $217.00Low
3/25/2022SVB LeerinkLower Price TargetUnderperform$81.00 ➝ $80.00High
3/7/2022Deutsche Bank AktiengesellschaftLower Price TargetHold$175.00 ➝ $155.00High
2/28/2022Morgan StanleyLower Price TargetEqual Weight$213.00 ➝ $205.00High
2/25/2022Jefferies Financial GroupLower Price Target$200.00 ➝ $170.00Low
2/25/2022BarclaysLower Price Target$404.00 ➝ $210.00Low
2/25/2022SVB LeerinkLower Price TargetUnderperform$85.00 ➝ $81.00Medium
2/1/2022Morgan StanleyLower Price TargetEqual Weight$315.00 ➝ $213.00Low
2/1/2022Redburn PartnersUpgradeSell ➝ NeutralLow
1/28/2022SVB LeerinkLower Price TargetUnderperform$86.00 ➝ $85.00High
1/26/2022Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$175.00High
1/21/2022UBS GroupInitiated CoverageNeutral$221.00High
1/21/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$135.00 ➝ $180.00High
1/18/2022Morgan StanleyBoost Price TargetEqual Weight$313.00 ➝ $315.00High
1/6/2022ArgusLower Price Target$420.00 ➝ $350.00Low
12/23/2021SVB LeerinkReiterated RatingSellLow
12/6/2021CowenInitiated CoverageMarket Perform$250.00High
11/8/2021Wolfe ResearchInitiated CoverageOutperform$304.00Medium
11/5/2021SVB LeerinkBoost Price TargetUnderperform$85.00 ➝ $86.00High
11/5/2021Morgan StanleyLower Price TargetEqual Weight$337.00 ➝ $313.00High
11/5/2021Jefferies Financial GroupLower Price TargetHold$375.00 ➝ $325.00High
11/5/2021The Goldman Sachs GroupReiterated RatingBuy$395.00High
11/5/2021Piper SandlerLower Price TargetOverweight$348.00High
10/22/2021Deutsche Bank AktiengesellschaftInitiated CoverageSell$250.00Medium
10/15/2021Piper SandlerUpgradeNeutral ➝ OverweightHigh
9/12/2021SVB LeerinkReiterated RatingSellHigh
9/7/2021Morgan StanleyBoost Price TargetEqual Weight$190.00 ➝ $337.00Medium
8/6/2021Piper SandlerDowngradeOverweight ➝ NeutralLow
8/5/2021OppenheimerDowngradeOutperform ➝ Market PerformMedium
7/15/2021Jefferies Financial GroupBoost Price TargetPositive ➝ Hold$170.00 ➝ $250.00High
7/7/2021Chardan CapitalReiterated RatingBuyHigh
6/24/2021ArgusBoost Price TargetBuy$200.00 ➝ $230.00Medium
5/7/2021Chardan CapitalBoost Price TargetBuy$182.00 ➝ $188.00Low
5/7/2021Morgan StanleyLower Price TargetEqual Weight$201.00 ➝ $190.00Low
5/7/2021BarclaysBoost Price TargetOverweight$178.00 ➝ $194.00Low
5/7/2021The Goldman Sachs GroupBoost Price TargetBuy$206.00 ➝ $228.00Low
5/6/2021Piper SandlerLower Price TargetOverweight$234.00 ➝ $231.00Low
5/5/2021Jefferies Financial GroupReiterated RatingHoldHigh
4/21/2021Piper SandlerReiterated RatingOverweight$208.00 ➝ $234.00High
4/18/2021SVB LeerinkReiterated RatingSellHigh
4/16/2021Needham & Company LLCReiterated RatingHoldHigh
4/15/2021Piper SandlerBoost Price TargetOverweight$208.00 ➝ $234.00Medium
3/15/2021Piper SandlerReiterated RatingOverweight$208.00Medium
3/1/2021Chardan CapitalBoost Price TargetPositive ➝ Buy$107.00 ➝ $182.00Low
2/26/2021BarclaysBoost Price Target$169.00 ➝ $178.00Low
2/26/2021Brookline Capital ManagementBoost Price TargetBuy$180.00 ➝ $205.00Low
2/26/2021Bank of AmericaReiterated RatingSell$140.00High
2/25/2021Morgan StanleyLower Price TargetEqual Weight$215.00 ➝ $201.00High
2/18/2021Jefferies Financial GroupBoost Price Target$150.00 ➝ $180.00Medium
2/18/2021Morgan StanleyBoost Price TargetEqual Weight$150.00 ➝ $215.00High
2/17/2021Piper SandlerBoost Price Target$170.00 ➝ $208.00Low
2/1/2021OppenheimerBoost Price TargetOutperform$178.00 ➝ $206.00Low
2/1/2021Wells Fargo & CompanyBoost Price TargetOverweight ➝ Equal Weight$129.00 ➝ $145.00Low
2/1/2021SVB LeerinkBoost Price TargetUnderperform$69.00 ➝ $80.00Low
2/1/2021Bank of AmericaDowngradeNeutral ➝ Underperform$150.00Low
1/22/2021Bank of AmericaBoost Price TargetNeutral$130.00 ➝ $140.00Low
1/6/2021Piper SandlerReiterated RatingOverweight$166.00 ➝ $170.00N/A
12/21/2020SVB LeerinkBoost Price TargetPositive ➝ Underperform$60.00 ➝ $69.00High
12/21/2020OppenheimerBoost Price TargetOutperform$157.00 ➝ $178.00High
12/18/2020BarclaysBoost Price TargetOverweight$84.00 ➝ $169.00Low
12/16/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$100.00 ➝ $150.00N/A
12/15/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$90.00 ➝ $150.00High
12/11/2020The Goldman Sachs GroupReiterated RatingBuy$139.00Medium
12/9/2020Needham & Company LLCDowngradeBuy ➝ HoldHigh
12/3/2020Bank of AmericaBoost Price Target$105.00 ➝ $150.00High
12/1/2020ArgusBoost Price TargetHold ➝ Buy$88.00 ➝ $200.00High
11/30/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$92.00 ➝ $129.00High
11/25/2020The Goldman Sachs GroupBoost Price Target$107.00 ➝ $139.00High
11/24/2020SVB LeerinkBoost Price TargetUnderperform$59.00 ➝ $60.00Low
11/23/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$92.00Low
11/17/2020Redburn PartnersInitiated CoverageSellMedium
11/17/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$109.00Medium
11/16/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$93.00 ➝ $107.00High
11/16/2020OppenheimerBoost Price TargetOutperform$108.00 ➝ $157.00High
11/16/2020Piper SandlerBoost Price TargetOverweight$136.00 ➝ $166.00High
11/11/2020ArgusBoost Price TargetBuy$80.00 ➝ $88.00High
11/11/2020Morgan StanleyBoost Price TargetOverweight$90.00 ➝ $100.00High
10/8/2020Chardan CapitalLower Price TargetBuy$95.00 ➝ $93.00Low
9/24/2020SVB LeerinkReiterated RatingSell$41.00High
9/8/2020SVB LeerinkDowngradeMarket Perform ➝ Underperform$58.00 ➝ $41.00High
8/12/2020Jefferies Financial GroupReiterated RatingBuy$90.00Medium
8/12/2020OppenheimerReiterated RatingBuy$108.00Medium
8/12/2020SVB LeerinkLower Price TargetMarket Perform$60.00 ➝ $58.00High
8/12/2020Chardan CapitalReiterated RatingBuy$95.00High
8/6/2020Chardan CapitalReiterated RatingBuy$95.00Low
8/6/2020SVB LeerinkLower Price TargetMarket Perform$65.00 ➝ $60.00Medium
8/6/2020JPMorgan Chase & Co.Reiterated RatingHoldMedium
8/5/2020Needham & Company LLCInitiated CoverageBuy$94.00Medium
7/27/2020Chardan CapitalReiterated RatingBuy$95.00High
7/27/2020SunTrust BanksInitiated CoverageBuy$120.00High
7/27/2020The Goldman Sachs GroupSet Price TargetBuy$105.00Medium
7/27/2020BMO Capital MarketsBoost Price TargetOutperform$94.00 ➝ $112.00Low
7/24/2020OppenheimerInitiated CoverageBuy$108.00High
7/23/2020SVB LeerinkInitiated CoverageMarket Perform$65.00High
7/20/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$60.00 ➝ $89.00High
7/15/2020Needham & Company LLCInitiated CoverageBuy$94.00N/A
7/15/2020OppenheimerInitiated CoverageBuy$108.00N/A
7/15/2020Piper SandlerBoost Price Target$100.00 ➝ $134.00High
7/15/2020Chardan CapitalBoost Price TargetBuy$84.00 ➝ $95.00N/A
7/13/2020Brookline Capital ManagementReiterated RatingBuy$95.00High
7/13/2020Jefferies Financial GroupInitiated CoverageBuy$90.00N/A
6/30/2020ArgusInitiated CoverageBuy$80.00N/A
6/25/2020Chardan CapitalReiterated RatingBuy$84.00N/A
6/12/2020Chardan CapitalReiterated RatingBuy$84.00N/A
6/11/2020Needham & Company LLCReiterated RatingBuy$94.00N/A
6/8/2020BarclaysInitiated CoverageOverweight$68.00N/A
6/3/2020Bank of AmericaLower Price Target$80.00 ➝ $75.00Medium
6/2/2020OppenheimerReiterated RatingBuy$108.00N/A
5/30/2020Chardan CapitalReiterated RatingBuy$52.00N/A
5/20/2020Morgan StanleyBoost Price TargetOverweight$37.00 ➝ $90.00High
5/19/2020Bank of AmericaBoost Price TargetNeutral$70.00 ➝ $95.00N/A
5/19/2020BMO Capital MarketsBoost Price TargetOutperform$83.00 ➝ $112.00N/A
5/18/2020Needham & Company LLCInitiated CoverageBuy$94.00N/A
5/18/2020OppenheimerBoost Price TargetOutperform$62.00 ➝ $108.00N/A
5/18/2020Piper SandlerBoost Price TargetOverweight$57.00 ➝ $102.00N/A
5/18/2020The Goldman Sachs GroupBoost Price TargetBuy$63.00 ➝ $105.00N/A
5/12/2020JPMorgan Chase & Co.Reiterated RatingBuy$60.00N/A
5/11/2020Roth CapitalBoost Price TargetBuy$41.00 ➝ $68.00N/A
5/8/2020OppenheimerBoost Price TargetOutperform$43.00 ➝ $62.00N/A
5/7/2020Needham & Company LLCBoost Price TargetBuy$35.00 ➝ $58.00N/A
5/1/2020Piper SandlerReiterated RatingBuy$57.00N/A
4/30/2020BMO Capital MarketsInitiated CoverageOutperform$83.00Medium
4/29/2020BMO Capital MarketsInitiated CoverageOutperformN/A
4/28/2020Chardan CapitalBoost Price TargetBuy$40.00 ➝ $52.00N/A
4/21/2020OppenheimerInitiated CoverageBuy$43.00N/A
4/17/2020JPMorgan Chase & Co.Reiterated RatingBuyN/A
4/17/2020Piper SandlerBoost Price Target$34.00 ➝ $57.00High
4/16/2020Roth CapitalBoost Price Target$33.00 ➝ $41.00High
4/15/2020Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $37.00High
4/15/2020Chardan CapitalReiterated RatingBuy$40.00N/A
4/15/2020OppenheimerBoost Price TargetOutperform$31.00 ➝ $43.00N/A
4/14/2020Piper SandlerReiterated RatingBuyN/A
3/30/2020Piper SandlerReiterated RatingBuy$34.00N/A
3/24/2020Needham & Company LLCReiterated RatingBuy$35.00N/A
3/16/2020Piper SandlerReiterated RatingBuy$32.00N/A
3/16/2020Chardan CapitalReiterated RatingBuy$40.00N/A
3/5/2020Chardan CapitalReiterated RatingBuy$40.00N/A
3/5/2020Bank of AmericaDowngradeBuy ➝ Neutral$32.00N/A
2/27/2020Roth CapitalBoost Price Target$24.00 ➝ $33.00High
2/26/2020Needham & Company LLCBoost Price TargetBuy$28.00 ➝ $35.00High
2/25/2020Piper SandlerReiterated RatingBuy$32.00N/A
2/25/2020Chardan CapitalReiterated RatingBuy$40.00N/A
2/11/2020Chardan CapitalReiterated RatingBuy$40.00N/A
1/22/2020Piper SandlerReiterated RatingBuy$32.00N/A
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuyN/A
1/10/2020Chardan CapitalReiterated RatingBuy$40.00N/A
1/2/2020Morgan StanleyInitiated CoverageOverweight$29.00N/A
1/2/2020BarclaysInitiated CoverageOverweight$20.00N/A
1/2/2020Bank of AmericaInitiated CoverageBuy$20.00N/A
1/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$22.00N/A
1/2/2020Needham & Company LLCInitiated CoverageBuy$28.00N/A
1/2/2020The Goldman Sachs GroupInitiated CoverageBuy$25.00N/A
1/2/2020Piper Jaffray CompaniesInitiated CoverageOverweight$24.00N/A
12/3/2019Bank of AmericaReiterated RatingBuy$29.00High
12/3/2019Bank of AmericaInitiated CoverageBuy$29.00N/A
11/6/2019Needham & Company LLCReiterated RatingBuy$28.00N/A
10/25/2019Roth CapitalReiterated RatingBuyLow
10/25/2019Roth CapitalInitiated CoverageBuy$24.00N/A
9/15/2019Chardan CapitalReiterated RatingBuyLow
9/15/2019JPMorgan Chase & Co.Reiterated RatingBuyN/A
9/13/2019Needham & Company LLCSet Price TargetBuy$28.00N/A
9/13/2019Chardan CapitalSet Price TargetBuy$40.00N/A
9/13/2019Piper Jaffray CompaniesReiterated RatingBuy$30.00 ➝ $32.00N/A
8/16/2019Piper Jaffray CompaniesSet Price TargetBuy$30.00N/A
8/12/2019Needham & Company LLCReiterated RatingBuy$28.00Medium
8/11/2019JPMorgan Chase & Co.Reiterated RatingBuy$24.00Medium
8/9/2019Morgan StanleySet Price TargetBuy$30.00N/A
6/2/2019Chardan CapitalReiterated RatingBuy$40.00High
5/29/2019OppenheimerBoost Price TargetOutperform$27.00 ➝ $31.00N/A
5/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$24.00 ➝ $30.00High
4/7/2019Chardan CapitalReiterated RatingBuyLow
4/5/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$40.00High
3/19/2019OppenheimerReiterated RatingBuyHigh
1/10/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
1/2/2019OppenheimerInitiated CoverageOutperform$27.00High
1/2/2019Morgan StanleyInitiated CoverageOverweight ➝ Overweight$29.00Low
1/2/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$28.00High
1/2/2019BarclaysInitiated CoverageOverweight ➝ Overweight$20.00Medium
1/2/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$20.00Medium
1/2/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$22.00Medium
1/2/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$25.00Medium
1/2/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$24.00Medium
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 90 positive mentions
  • 24 negative mentions
  • 9 very negative mentions
  • 13 very positive mentions
  • 54 positive mentions
  • 20 negative mentions
  • 3 very negative mentions
  • 14 very positive mentions
  • 52 positive mentions
  • 13 negative mentions
  • 9 very negative mentions
  • 11 very positive mentions
  • 62 positive mentions
  • 13 negative mentions
  • 2 very negative mentions
  • 10 very positive mentions
  • 70 positive mentions
  • 6 negative mentions
  • 12 very negative mentions
  • 14 very positive mentions
  • 57 positive mentions
  • 8 negative mentions
  • 5 very negative mentions
  • 8 very positive mentions
  • 40 positive mentions
  • 10 negative mentions
  • 2 very negative mentions
  • 13 very positive mentions
  • 59 positive mentions
  • 8 negative mentions
  • 3 very negative mentions

Current Sentiment

  • 13 very positive mentions
  • 59 positive mentions
  • 8 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Moderna logo
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $149.95
Low: $139.84
High: $151.00

50 Day Range

MA: $138.09
Low: $117.13
High: $155.05

52 Week Range

Now: $149.95
Low: $115.61
High: $497.49


168,983 shs

Average Volume

5,214,693 shs

Market Capitalization

$59.64 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Moderna?

The following Wall Street analysts have issued stock ratings on Moderna in the last twelve months: Argus, Bank of America Co., Barclays PLC, Chardan Capital, Cowen Inc, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Redburn Partners, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and Wolfe Research.
View the latest analyst ratings for MRNA.

What is the current price target for Moderna?

0 Wall Street analysts have set twelve-month price targets for Moderna in the last year. Their average twelve-month price target is $228.00, suggesting a possible upside of 52.1%.
View the latest price targets for MRNA.

What is the current consensus analyst rating for Moderna?

Moderna currently has 1 sell rating, 8 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MRNA, but not buy more shares or sell existing shares.
View the latest ratings for MRNA.

How do I contact Moderna's investor relations team?

Moderna's physical mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 714-6500 and its investor relations email address is [email protected] The official website for Moderna is Learn More about contacing Moderna investor relations.